Sensenonics Shares Are Trading Higher After the Company Announced FDA Clearance for Its Next-generation Eversense 365 Continuous Glucose Monitoring (CGM) System for People With Type 1 and Type 2 Diabetes Aged 18 Years Older.
Sensenonics Shares Are Trading Higher After the Company Announced FDA Clearance for Its Next-generation Eversense 365 Continuous Glucose Monitoring (CGM) System for People With Type 1 and Type 2 Diabetes Aged 18 Years Older.
瑞思诺公司的股票交投较高，因为该公司宣布其新一代Eversense 365持续血糖监测（CGM）系统获得FDA批准，适用于18岁及以上的1型和2型糖尿病患者。
Sensenonics Shares Are Trading Higher After the Company Announced FDA Clearance for Its Next-generation Eversense 365 Continuous Glucose Monitoring (CGM) System for People With Type 1 and Type 2 Diabetes Aged 18 Years Older.
瑞思诺公司的股票交投较高，因为该公司宣布其新一代Eversense 365持续血糖监测（CGM）系统获得FDA批准，适用于18岁及以上的1型和2型糖尿病患者。
资讯热榜
更新时间